American Association for Cancer Research
00085472can142097-sup-134824_1_supp_2875358_nk4k2d.pptx (160.76 kB)

Supplementary Figure S5 from Vacuolar-ATPase Inhibition Blocks Iron Metabolism to Mediate Therapeutic Effects in Breast Cancer

Download (160.76 kB)
posted on 2023-03-30, 23:02 authored by Lina S. Schneider, Karin von Schwarzenberg, Thorsten Lehr, Melanie Ulrich, Rebekka Kubisch-Dohmen, Johanna Liebl, Dirk Trauner, Dirk Menche, Angelika M. Vollmar

Supplementary Figure S5. Archazolid induces ferritin, transferrin and RRM2 mRNA levels.



Generalized strategies to improve breast cancer treatment remain of interest to develop. In this study, we offer preclinical evidence of an important metabolic mechanism underlying the antitumor activity of inhibitors of the vacuolar-type ATPase (V-ATPase), a heteromultimeric proton pump. Specifically, our investigations in the 4T1 model of metastatic breast cancer of the V-ATPase inhibitor archazolid suggested that its ability to trigger metabolic stress and apoptosis associated with tumor growth inhibition related to an interference with hypoxia-inducible factor-1α signaling pathways and iron metabolism. As a consequence of disturbed iron metabolism, archazolid caused S-phase arrest, double-stranded DNA breaks, and p53 stabilization, leading to apoptosis. Our findings link V-ATPase to cell-cycle progression and DNA synthesis in cancer cells, and highlight the basis for the clinical exploration of V-ATPase as a potentially generalizable therapy for breast cancer. Cancer Res; 75(14); 2863–74. ©2015 AACR.